BRIEF-Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Reuters

Jan 16, 2025

BRIEF-<a href="https://laohu8.com/S/ATRA">Atara Biotherapeutics</a> Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Jan 16 (Reuters) - Atara Biotherapeutics Inc ATRA.O:

ATARA BIOTHERAPEUTICS PROVIDES REGULATORY AND BUSINESS UPDATE ON EBVALLOTM (TABELECLEUCEL)
ATARA BIOTHERAPEUTICS INC: RECEIVED FDA COMPLETE RESPONSE LETTER $(CRL)$ SOLELY RELATED TO INSPECTION FINDINGS AT THIRD-PARTY MANUFACTURER
ATARA BIOTHERAPEUTICS INC: CRL DID NOT IDENTIFY DEFICIENCIES RELATED TO CLINICAL EFFICACY OR SAFETY DATA IN BLA
ATARA BIOTHERAPEUTICS INC: ENGAGED ADVISOR TO SUPPORT EXPLORATION OF ALL STRATEGIC OPTIONS
ATARA BIOTHERAPEUTICS: GOT INTO NON-BINDING TERM SHEET WITH REDMILE GROUP TO PROVIDE UP TO $15 MILLION IN FUNDING
ATARA BIOTHERAPEUTICS: INTENDS TO SUSPEND ALL CAR-T ACTIVITIES, SIGNIFICANTLY CUT EXPENSES IF RESOLUTION NOT REACHED FOR FUNDING FOR PROGRAMS IN Q1

Source text: ID:nBw4SHWVza

Further company coverage: ATRA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503994946"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503994946\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503994946?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-16 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503994946","market":"us","top_or_hot":-1,"title":"BRIEF-Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/ATRA\">Atara Biotherapeutics</a> Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)</title></head><body><p><span>Jan 16 (Reuters)</span><span> - </span>Atara Biotherapeutics Inc <span>ATRA.O</span>:</p><ul><li><p>ATARA BIOTHERAPEUTICS PROVIDES REGULATORY AND BUSINESS UPDATE ON EBVALLOTM (TABELECLEUCEL)</p></li><li><p>ATARA BIOTHERAPEUTICS INC: RECEIVED FDA COMPLETE RESPONSE LETTER <a href=\"https://laohu8.com/S/CRL\">$(CRL)$</a> SOLELY RELATED TO INSPECTION FINDINGS AT THIRD-PARTY MANUFACTURER</p></li><li><p>ATARA BIOTHERAPEUTICS INC: CRL DID NOT IDENTIFY DEFICIENCIES RELATED TO CLINICAL EFFICACY OR SAFETY DATA IN BLA</p></li><li><p>ATARA BIOTHERAPEUTICS INC: ENGAGED ADVISOR TO SUPPORT EXPLORATION OF ALL STRATEGIC OPTIONS</p></li><li><p>ATARA BIOTHERAPEUTICS: GOT INTO NON-BINDING TERM SHEET WITH REDMILE GROUP TO PROVIDE UP TO $15 MILLION IN FUNDING</p></li><li><p>ATARA BIOTHERAPEUTICS: INTENDS TO SUSPEND ALL CAR-T ACTIVITIES, SIGNIFICANTLY CUT EXPENSES IF RESOLUTION NOT REACHED FOR FUNDING FOR PROGRAMS IN Q1</p></li></ul><p>Source text: <span>ID:nBw4SHWVza</span></p><p>Further company coverage: <span>ATRA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-16 21:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/ATRA\">Atara Biotherapeutics</a> Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)</title></head><body><p><span>Jan 16 (Reuters)</span><span> - </span>Atara Biotherapeutics Inc <span>ATRA.O</span>:</p><ul><li><p>ATARA BIOTHERAPEUTICS PROVIDES REGULATORY AND BUSINESS UPDATE ON EBVALLOTM (TABELECLEUCEL)</p></li><li><p>ATARA BIOTHERAPEUTICS INC: RECEIVED FDA COMPLETE RESPONSE LETTER <a href=\"https://laohu8.com/S/CRL\">$(CRL)$</a> SOLELY RELATED TO INSPECTION FINDINGS AT THIRD-PARTY MANUFACTURER</p></li><li><p>ATARA BIOTHERAPEUTICS INC: CRL DID NOT IDENTIFY DEFICIENCIES RELATED TO CLINICAL EFFICACY OR SAFETY DATA IN BLA</p></li><li><p>ATARA BIOTHERAPEUTICS INC: ENGAGED ADVISOR TO SUPPORT EXPLORATION OF ALL STRATEGIC OPTIONS</p></li><li><p>ATARA BIOTHERAPEUTICS: GOT INTO NON-BINDING TERM SHEET WITH REDMILE GROUP TO PROVIDE UP TO $15 MILLION IN FUNDING</p></li><li><p>ATARA BIOTHERAPEUTICS: INTENDS TO SUSPEND ALL CAR-T ACTIVITIES, SIGNIFICANTLY CUT EXPENSES IF RESOLUTION NOT REACHED FOR FUNDING FOR PROGRAMS IN Q1</p></li></ul><p>Source text: <span>ID:nBw4SHWVza</span></p><p>Further company coverage: <span>ATRA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nTUA3DHNHT:1","article_id":"2503994946","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503994946","pubTimestamp":1737034616,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)Jan 16 (Reuters) - Atara Biotherapeutics Inc ATRA.O:ATARA BIOTHERAPEUTICS PROVIDES REGULATORY AND BUSINE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATRA":"Atara Biotherapeutics"},"translate_title":"简介-Atara Biotherapeutics提供EBVALLOTM(tabelecleucel)的监管和业务更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATRA":0.9},"content_text":"BRIEF-Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)Jan 16 (Reuters) - Atara Biotherapeutics Inc ATRA.O:ATARA BIOTHERAPEUTICS PROVIDES REGULATORY AND BUSINESS UPDATE ON EBVALLOTM (TABELECLEUCEL)ATARA BIOTHERAPEUTICS INC: RECEIVED FDA COMPLETE RESPONSE LETTER $(CRL)$ SOLELY RELATED TO INSPECTION FINDINGS AT THIRD-PARTY MANUFACTURERATARA BIOTHERAPEUTICS INC: CRL DID NOT IDENTIFY DEFICIENCIES RELATED TO CLINICAL EFFICACY OR SAFETY DATA IN BLAATARA BIOTHERAPEUTICS INC: ENGAGED ADVISOR TO SUPPORT EXPLORATION OF ALL STRATEGIC OPTIONSATARA BIOTHERAPEUTICS: GOT INTO NON-BINDING TERM SHEET WITH REDMILE GROUP TO PROVIDE UP TO $15 MILLION IN FUNDINGATARA BIOTHERAPEUTICS: INTENDS TO SUSPEND ALL CAR-T ACTIVITIES, SIGNIFICANTLY CUT EXPENSES IF RESOLUTION NOT REACHED FOR FUNDING FOR PROGRAMS IN Q1Source text: ID:nBw4SHWVzaFurther company coverage: ATRA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}